suphioglu-currentaspectsofthe-2020.pdf (449.8 kB)
Current aspects of the endocannabinoid system and targeted THC and CBD Phytocannabinoids as potential therapeutics for Parkinson’s and Alzheimer’s Diseases: a Review
journal contribution
posted on 2020-08-19, 00:00 authored by Ruwini CoorayRuwini Cooray, Veer GuptaVeer Gupta, Cenk SuphiogluCenk SuphiogluNeurodegeneration leading to Parkinson’s disease (PD) and Alzheimer’s disease (AD) has become a major health burden globally.
Current treatments mainly target controlling symptoms and there are no therapeutics available in clinical practice to preventing the
neurodegeneration or inducing neuronal repairing. Thus, the demand of novel research for the two disorders is imperative. This literature review aims to provide a collection of published work on PD and AD and current uses of endocannabinoid system (ECS) as a potential drug target for neurodegeneration. PD is frequently treated with L-DOPA and deep brain stimulation. Recent gene modification and remodelling techniques, such as CRISPR through human embryonic stem cells and induced pluripotent stem cells, have shown promising strategy for personalised medicine. AD characterised by extracellular deposits of amyloid β-senile plaques and neurofibrillary tangles of tau protein commonly uses choline acetyltransferase enhancers as therapeutics. The ECS is currently being studied as PD and AD drug targets where overexpression of ECS receptors exerted neuroprotection against PD and reduced
neuroinflammation in AD. The delta-9-tetrahydrocannabinoid (Δ9
-THC) and cannabidiol (CBD) cannabinoids of plant Cannabis sativa have shown neuroprotection upon PD and AD animal models yet triggered toxic effects on patients when administered directly. Therefore, understanding the precise molecular cascade following cannabinoid treatment is suggested, focusing especially on gene expression to identify drug targets for preventing and repairing neurodegeneration.
Current treatments mainly target controlling symptoms and there are no therapeutics available in clinical practice to preventing the
neurodegeneration or inducing neuronal repairing. Thus, the demand of novel research for the two disorders is imperative. This literature review aims to provide a collection of published work on PD and AD and current uses of endocannabinoid system (ECS) as a potential drug target for neurodegeneration. PD is frequently treated with L-DOPA and deep brain stimulation. Recent gene modification and remodelling techniques, such as CRISPR through human embryonic stem cells and induced pluripotent stem cells, have shown promising strategy for personalised medicine. AD characterised by extracellular deposits of amyloid β-senile plaques and neurofibrillary tangles of tau protein commonly uses choline acetyltransferase enhancers as therapeutics. The ECS is currently being studied as PD and AD drug targets where overexpression of ECS receptors exerted neuroprotection against PD and reduced
neuroinflammation in AD. The delta-9-tetrahydrocannabinoid (Δ9
-THC) and cannabidiol (CBD) cannabinoids of plant Cannabis sativa have shown neuroprotection upon PD and AD animal models yet triggered toxic effects on patients when administered directly. Therefore, understanding the precise molecular cascade following cannabinoid treatment is suggested, focusing especially on gene expression to identify drug targets for preventing and repairing neurodegeneration.
History
Journal
Molecular NeurobiologyPublisher
SpringerLocation
Heidelberg, GermanyPublisher DOI
Link to full text
ISSN
0893-7648eISSN
1559-1182Language
engPublication classification
C Journal article; C1 Refereed article in a scholarly journalCopyright notice
2020, The AuthorsUsage metrics
Categories
No categories selectedKeywords
Parkinson’s diseaseAlzheimer’s diseaseEndocannabinoid systemTHCCBDScience & TechnologyLife Sciences & BiomedicineNeurosciencesNeurosciences & NeurologyParkinson's diseaseAlzheimer's diseaseRECEPTOR MESSENGER-RNAACID AMIDE HYDROLASECANNABINOID RECEPTORAMYLOID-BETAANIMAL-MODELDOUBLE-BLINDMOUSE MODELBASAL GANGLIACANNABIDIOLEXPRESSION
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC